Redhill Biopharma Ltd ADR buy marge
Start price
26.07.17
/
50%
€9.56
Target price
26.01.18
€22.55
Performance (%)
-36.27%
End price
26.01.18
€6.09
Summary
This prediction ended on 26.01.18 with a price of €6.09. Massive losses of -36.27% were the result for the BUY prediction by marge. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Redhill Biopharma Ltd ADR | - | - | - | - |
| iShares Core DAX® | 1.080% | -2.933% | 12.885% | 14.247% |
| iShares Nasdaq 100 | 0.362% | 7.015% | 36.826% | 57.151% |
| iShares Nikkei 225® | -1.155% | -1.155% | 5.073% | 3.799% |
| iShares S&P 500 | 0.806% | 4.388% | 30.269% | 49.772% |
Comments by marge for this prediction
In the thread Redhill Biopharma Ltd ADR diskutieren
RDHL with several important catalysts in the near future.
It should file a NDA for Rizaport in October. This compound offers certain advantages over conventional treatment, especially for migraine patients who are experiencing nausea as is often the case with this condition. It has already seen its European marketing application approved. An update September. on RHB-104 to treat Crohn's disease should hit early in August. If the study shows overwhelming efficacy there may not be a need for further trials. Full data results should be disclosed in September.
At the current cash burnrate, the company is well-funded until late in 2018. With only a $180 millionmarket cap, the market seems to be woefully undervaluing this name given itspipeline and upcoming catalysts.
(Laufzeit überschritten)
Stopped prediction by marge for Redhill Biopharma Ltd ADR
Redhill Biopharma Ltd ADR
Start price
Target price
Perf. (%)
€6.84
29.08.18
29.08.18
€14.43
29.08.19
29.08.19
-4.75%
29.08.19
29.08.19
